Shenzhen Salubris Pharmaceuticals Co., Ltd. Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Shenzhen China (1998)

Organization Overview

First Clinical Trial
2016
NCT02897037
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Active Ingredients

Drugs in Phase 4 Trials (1)

clopidogrel (plavix) (1 trial)

Drugs in Phase 3 Trials (4)

alogliptin (nesina) (2 trials)

bivalirudin (angiomax) (1 trial)

enarodustat (1 trial)

heparin (liquaemin) (1 trial)

Drugs in Phase 2 Trials (2)

parathyroid hormone (Natpara) (1 trial)

teriparatide (2 trials)

Drugs in Phase 1 Trials (2)

sal001 (1 trial)

sev-hfgf2/df (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arterial Occlusive Diseases (Phase 1)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Heart Diseases (Phase 4)

Infarction (Phase 3)

Ischemia (Phase 1)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 4)

Osteoporosis (Phase 2)

Osteoporosis, Postmenopausal (Phase 2)

Peripheral Arterial Disease (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 8
  • # of Trial APIs: 9